A citation-based method for searching scientific literature

Solveig Skovlund Groen, Dovile Sinkeviciute, Anne-Christine Bay-Jensen, Christian S Thudium, Morten A Karsdal, Simon Francis Thomsen, Georg Schett, Signe Holm Nielsen. Autoimmun Rev 2021
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
Dennis G McGonagle, Iain B McInnes, Bruce W Kirkham, Jonathan Sherlock, Robert Moots. Ann Rheum Dis 2019
80
66

Mechanism of New Bone Formation in Axial Spondyloarthritis.
Denis Poddubnyy, Joachim Sieper. Curr Rheumatol Rep 2017
40
66

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados,[...]. Ann Rheum Dis 2017
821
33

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Feng Huang, Fei Sun, Wei-Guo Wan, Li-Jun Wu, Ling-Li Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang,[...]. Chin Med J (Engl) 2020
13
33

Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Hong Ki Min, Hae-Rim Kim, Sang-Heon Lee, Yeon Sik Hong, Moon-Young Kim, Sung-Hwan Park, Kwi Young Kang. Rheumatology (Oxford) 2021
6
33

Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Khalaf Kridin, Yochai Schonmann, Arie Solomon, Giovanni Damiani, Dana Tzur Bitan, Erez Onn, Orly Weinstein, Arnon Dov Cohen. J Dermatolog Treat 2022
11
33

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Dominique Baeten, Joachim Sieper, Paul Emery, Aimee Readie, Ruvie Martin, Shephard Mpofu, Hanno B Richards. Ann Rheum Dis 2017
163
33

Secukinumab for rheumatology: development and its potential place in therapy.
Marije I Koenders, Wim B van den Berg. Drug Des Devel Ther 2016
23
33

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
Walter P Maksymowych, Vibeke Strand, Peter Nash, Yusuf Yazici, Howard Thom, Matthias Hunger, Chrysostomos Kalyvas, Kunal K Gandhi, Brian Porter, Steffen M Jugl. Eur J Rheumatol 2018
6
33

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.
R B Warren, K Reich, R G Langley, B Strober, D Gladman, A Deodhar, T Bachhuber, W Bao, E Altemeyer, S Hussain,[...]. Br J Dermatol 2018
50
33

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.
Ana-Maria Orbai, Iain B McInnes, Laura C Coates, M Elaine Husni, Dafna D Gladman, Laure Gossec, Luminita Pricop, Olivier Chambenoit, Xiangyi Meng, Philip J Mease. J Rheumatol 2020
5
33

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Raphael Micheroli, Christoph Tellenbach, Almut Scherer, Kristina Bürki, Karin Niederman, Michael J Nissen, Pascal Zufferey, Pascale Exer, Burkhard Möller, Diego Kyburz,[...]. Ann Rheum Dis 2020
25
33

Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients.
Ioana A Onac, Benjamin D Clarke, Cristina Tacu, Mark Lloyd, Vijay Hajela, Thomas Batty, Jamie Thoroughgood, Sandra Smith, Hannah Irvine, Diane Hill,[...]. Rheumatology (Oxford) 2021
2
50

Tumor necrosis factor inhibitors - state of knowledge.
Krzysztof Lis, Olga Kuzawińska, Ewa Bałkowiec-Iskra. Arch Med Sci 2014
114
33

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Yoshiya Tanaka, Bruno Fautrel, Edward C Keystone, Robert A Ortmann, Li Xie, Baojin Zhu, Maher Issa, Himanshu Patel, Carol L Gaich, Stephanie de Bono,[...]. Ann Rheum Dis 2019
13
33

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella,[...]. Ann Rheum Dis 2021
37
33

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
Philip J Mease, Mei Liu, Sabrina Rebello, Winnie Hua, Robert R McLean, Esther Yi, Yujin Park, Alexis Ogdie. ACR Open Rheumatol 2020
13
33

One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Bente Glintborg, Ulf Lindström, Daniela Di Giuseppe, Sella Aarrestad Provan, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen, Johan K Wallman, Kalle Aaltonen, Anna-Mari Hokkanen,[...]. Arthritis Care Res (Hoboken) 2022
8
33

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter. Arthritis Res Ther 2017
114
33

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Elena Conesa-Nicolás, María Henar García-Lagunar, Sara Núñez-Bracamonte, María Sergia García-Simón, María Carmen Mira-Sirvent. Farm Hosp 2020
2
50

Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Gennadiy A Katsevman, Gonzalo Mariscal, Carlos Barrios, Pedro Domenech-Fernández, Conrad Ziembinski, Sanjay Bhatia. Monoclon Antib Immunodiagn Immunother 2020
1
100

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Rubén Queiro Silva, Susana Armesto, Carmen González Vela, Cristina Naharro Fernández, Miguel Angel González-Gay. Dermatol Ther 2020
26
33

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs.
Yu Zhou, Jinhui Ma, Juncheng Ge, Bailiang Wang, Debo Yue, Weiguo Wang. Mediators Inflamm 2020
2
50

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.
Jürgen Braun, Atul Deodhar, Robert Landewé, Xenofon Baraliakos, Corinne Miceli-Richard, Joachim Sieper, Erhard Quebe-Fehling, Ruvie Martin, Brian Porter, Kunal K Gandhi,[...]. RMD Open 2018
18
33

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
583
33

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
148
33

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Alan J Kivitz, Ulf Wagner, Eva Dokoupilova, Jerzy Supronik, Ruvie Martin, Zsolt Talloczy, Hanno B Richards, Brian Porter. Rheumatol Ther 2018
48
33

Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Xenofon Baraliakos, Mikkel Østergaard, Lianne S Gensler, Denis Poddubnyy, Eun Young Lee, Uta Kiltz, Ruvie Martin, Hiroshi Sawata, Aimee Readie, Brian Porter. Clin Drug Investig 2020
19
33

Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
Atul A Deodhar, Corine Miceli-Richard, Xenofon Baraliakos, Helena Marzo-Ortega, Dafna D Gladman, Ricardo Blanco, Ayan Das Gupta, Ruvie Martin, Jorge Safi, Brian Porter,[...]. ACR Open Rheumatol 2020
14
33

Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.
Timo Purmonen, Soili Törmälehto, Hanna Wahlman, Kari Puolakka. J Med Econ 2019
5
33


Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
Brigitte Michelsen, Ulf Lindström, Catalin Codreanu, Adrian Ciurea, Jakub Zavada, Anne Gitte Loft, Manuel Pombo-Suarez, Fatos Onen, Tore K Kvien, Ziga Rotar,[...]. RMD Open 2020
12
33

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Dominique Baeten, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Paul Emery, Désirée van der Heijde, Iain McInnes, Jacob M van Laar, Robert Landewé, Paul Wordsworth,[...]. Lancet 2013
426
33

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
James C-C Wei, Dominique Baeten, Joachim Sieper, Atul Deodhar, Vaishali Bhosekar, Ruvie Martin, Brian Porter. Int J Rheum Dis 2017
21
33

Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study.
Astrid van Tubergen, Sofia Ramiro, Désirée van der Heijde, Maxime Dougados, Herman Mielants, Robert Landewé. Ann Rheum Dis 2012
102
33


Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, Kristian Reich, Atul A Deodhar, Iain B McInnes, Brian Porter, Ayan Das Gupta, Luminita Pricop, Todd Fox. Ann Rheum Dis 2019
97
33

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Denis Poddubnyy, Paul Emery, Eumorphia M Delicha, Zsolt Talloczy, Brian Porter. Rheumatology (Oxford) 2019
74
33

Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Ilke Coskun Benlidayi, Behice Kurtaran, Emre Tirasci, Rengin Guzel. Rheumatol Int 2020
20
33

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Atul Deodhar, Ricardo Blanco, Eva Dokoupilová, Stephen Hall, Hideto Kameda, Alan J Kivitz, Denis Poddubnyy, Marleen van de Sande, Anna S Wiksten, Brian O Porter,[...]. Arthritis Rheumatol 2021
56
33

Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
Algün Polat Ekinci, Gizem Pehlivan, Mehmet Onur Gökalp. Dermatol Ther 2021
14
33

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks.
Atul Deodhar, Philip Mease, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Steven Lauzon, Ann Leung, Victoria Navarro-Compán. BMC Rheumatol 2021
2
50


Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
Helena Marzo-Ortega, Joachim Sieper, Alan Kivitz, Ricardo Blanco, Martin Cohen, Evie-Maria Delicha, Susanne Rohrer, Hanno Richards. RMD Open 2017
48
33

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Michael M Ward, Atul Deodhar, Lianne S Gensler, Maureen Dubreuil, David Yu, Muhammad Asim Khan, Nigil Haroon, David Borenstein, Runsheng Wang, Ann Biehl,[...]. Arthritis Care Res (Hoboken) 2019
93
33

Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Catia Duarte,[...]. Ann Rheum Dis 2022
46
33

Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
Xenofon Baraliakos, Babul Borah, Juergen Braun, Dominique Baeten, Didier Laurent, Joachim Sieper, Paul Emery, Iain B McInnes, Jacob M van Laar, Paul Wordsworth,[...]. Ann Rheum Dis 2016
56
33

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Karel Pavelka, Alan J Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O Porter, Anna Stefanska, Hanno B Richards,[...]. ACR Open Rheumatol 2020
15
33

Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
Angela Ceribelli, Francesca Motta, Matteo Vecellio, Natasa Isailovic, Francesco Ciccia, Carlo Selmi. Front Immunol 2021
7
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.